A study in the Journal of Biomedical Science reported an engineered ACE2 decoy receptor that neutralizes mutant and escape variants of SARS-CoV-2. The decoy binds spike protein across divergent strains, blocking viral entry in vitro and in animal challenge models. Authors demonstrate breadth against mutations that reduce monoclonal antibody efficacy and map key binding interactions that preserve neutralization. An ACE2 decoy acts as a soluble receptor trap; its variant-resistant binding profile suggests a complementary strategy to antibodies and vaccines for immediate passive protection and for immunocompromised populations.